S2492 - Relative to pharmaceutical access, costs and transparency
Joint Committee on Health Care Financing, Cindy F. Friedman, Nicholas A. Boldyga
Last updated 11 months ago
38 Co-Sponsors
For legislationfor legislationfor legislationfor legislationfor legislationfor legislationfor legislation to bring down the cost of prescription drugs; of Nicholas A. Boldyga relative to establishing a prescription drug rebate program for seniors; of Edward F. Coppinger and others relative to promoting comprehensive transparency in the pharmaceutical industry; of Kate Hogan relative to the pricing of prescription drugs; of Bradley H. Jones, Jr., and others that the Health Policy Commission and health insurers create listings of certain high cost prescription drugs and that the Attorney General require drug manufacturers to provide information to justify increases in costs; of Bradley H. Jones, Jr., and others for an investigation by a special commission (including members of the General Court) relative to contracts between the MassHealth program and pharmaceutical benefit managers; of John J. Lawn, Jr., and others relative to pharmacy benefit managers; of William M. Straus relative to drug prices paid by carriers; and of Alyson M. Sullivan-Almeida, Michael J. Soter and David F. DeCoste relative to pharmacy benefit managers reimbursements to pharmacies in the Commonwealth, reports the accompanying bill (Senate, No. 2492).
STATUS
Introduced